Erectile dysfunction remains one of the most common and distressing consequences of prostate cancer treatment, with significant implications for quality of life, psychological wellbeing, and long‑term survivorship. In this session, Professor Mike Kirby — a leading authority in sexual medicine, men’s health, and cardio‑metabolic disease — will provide an evidence‑based overview of the mechanisms driving erectile dysfunction in men treated for prostate cancer and the role of PDE5 inhibitors in supporting recovery.
Building on decades of clinical and academic expertise, Professor Kirby will explore emerging research demonstrating that PDE5 inhibitors may offer benefits beyond erectile function, including potential cardiovascular, metabolic, and urological effects. He will discuss how these findings could influence survivorship pathways, multidisciplinary follow‑up, and holistic care planning in secondary care settings.
The session will also address practical challenges in prescribing PDE5 inhibitors for prostate cancer survivors, including considerations for vulnerable populations, co‑morbidities, and gaps in current practice. Drawing on observational data and real‑world clinical experience, Professor Kirby will highlight how PDE5 inhibitors may contribute to improved long‑term outcomes, better patient experience, and more personalised survivorship care.
This session forms part of the Specialists Conference 2026 and is designed for secondary care nurses, clinical nurse specialists, doctors, and allied health professionals involved in prostate cancer treatment and survivorship support.
